PMID- 29493554
OWN - NLM
STAT- MEDLINE
DCOM- 20190218
LR  - 20190219
IS  - 1752-2978 (Electronic)
IS  - 1752-296X (Linking)
VI  - 25
IP  - 2
DP  - 2018 Apr
TI  - Elevated triglycerides and low high-density lipoprotein cholesterol level as 
      marker of very high risk in type 2 diabetes.
PG  - 118-129
LID - 10.1097/MED.0000000000000398 [doi]
AB  - PURPOSE OF REVIEW: The aim of this review is to describe in diabetic patients the 
      determinants underlying atherogenic dyslipidemia, a complex dyslipidemia defined 
      as the coexistence of fasting hypertriglyceridemia and low high-density 
      lipoprotein cholesterol level. Atherogenic dyslipidemia is often comorbid with 
      hyperglycemia in patients with the common form of type 2 diabetes mellitus 
      (T2DM), namely that associated with obesity, insulin resistance, hyperinsulinemia 
      and the metabolic syndrome phenotype. RECENT FINDINGS: The role of 
      triglyceride-rich lipoproteins, both fasting and nonfasting, is increasingly 
      considered as a direct driver of atherosclerosis in diabetic patients, even in 
      those receiving best standards of care, including low-density lipoprotein 
      cholesterol level adequately controlled by statins and/or ezetimibe. The residual 
      cardiovascular risk related to atherogenic dyslipidemia in T2DM patients can be 
      inferred from subgroup analysis of diabetic patients within landmark 
      lipid-lowering trials, or from T2DM-only trials, such as Fenofibrate Intervention 
      and Event Lowering in Diabetes study or Action to Control Cardiovascular Risk in 
      Diabetes-Lipid trial. SUMMARY: The presence of atherogenic dyslipidemia markedly 
      increases cardiovascular risk, and there is evidence that part of the residual 
      cardiovascular risk in T2DM can be safely and effectively reduced by fibrates. 
      Ongoing trials will determine whether new classes of drugs or dietary 
      intervention targeting hypertriglyceridemia (such as n-3 fatty acids or SPPARMalpha) 
      will reduce macro and microvascular residual risk in T2DM patients with 
      atherogenic dyslipidemia at inclusion.
FAU - Hermans, Michel P
AU  - Hermans MP
AD  - Division of Endocrinology & Nutrition, Cliniques universitaires St-Luc and 
      Institut de Recherche Experimentale et Clinique (IREC), Universite catholique de 
      Louvain, Brussels, Belgium.
FAU - Valensi, Paul
AU  - Valensi P
AD  - Department of Endocrinology-Diabetology-Nutrition, CRNH-IdF, CINFO, AP-HP, Jean 
      Verdier Hospital, Paris 13 University, Bondy, France.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Endocrinol Diabetes Obes
JT  - Current opinion in endocrinology, diabetes, and obesity
JID - 101308636
RN  - 0 (Biomarkers)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Triglycerides)
SB  - IM
MH  - Biomarkers/*blood
MH  - Cholesterol, HDL/*blood
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/*blood/epidemiology/*etiology
MH  - Dyslipidemias/blood/complications/epidemiology
MH  - Humans
MH  - Hypertriglyceridemia/blood/complications/epidemiology
MH  - Risk Factors
MH  - Triglycerides/*blood
EDAT- 2018/03/02 06:00
MHDA- 2019/02/20 06:00
CRDT- 2018/03/02 06:00
PHST- 2018/03/02 06:00 [entrez]
PHST- 2018/03/02 06:00 [pubmed]
PHST- 2019/02/20 06:00 [medline]
AID - 01266029-201804000-00009 [pii]
AID - 10.1097/MED.0000000000000398 [doi]
PST - ppublish
SO  - Curr Opin Endocrinol Diabetes Obes. 2018 Apr;25(2):118-129. doi: 
      10.1097/MED.0000000000000398.